Shawnte M. Mitchell Net Worth

Ms. Shawnte M. Mitchell biography

Shawnte M. Mitchell is the Exec. VP, Gen. Counsel & Sec. at Zogenix Inc.

What is the salary of Ms Mitchell?

As the Exec. VP and Gen. Counsel & Sec. of Zogenix Inc, the total compensation of Ms Mitchell at Zogenix Inc is $715,403. There are 6 executives at Zogenix Inc getting paid more, with Stephen Farr having the highest compensation of $10,346,800.

How old is Ms Mitchell?

Ms Mitchell is 43, she's been the Exec. VP and Gen. Counsel & Sec. of Zogenix Inc since . There are 22 older and no younger executives at Zogenix Inc. The oldest executive at Zogenix Inc is Cam Garner, 71, who is the Independent Chairman of the Board.

What's Ms Mitchell's mailing address?

Shawnte's mailing address filed with the SEC is C/O ZOGENIX, INC., 5959 HORTON STREET, SUITE 500, EMERYVILLE, CA, 94608.

Insiders trading at Zogenix Inc

Over the last 14 years, insiders at Zogenix Inc have traded over $5,100,850 worth of Zogenix Inc stock and bought 57,764,538 units worth $193,451,745 . The most active insiders traders include Advisors Llcperceptive Life..., Nicole Vitullo, and Jesse I Treu. On average, Zogenix Inc executives and independent directors trade stock every 34 days with the average trade being worth of $13,059,406. The most recent stock trade was executed by Erle T Mast on 1 February 2022, trading 1,250 units of ZGNX stock currently worth $15,000.

What does Zogenix Inc do?

Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company's first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.

Zogenix Inc executives and stock owners

Zogenix Inc executives and other stock owners filed with the SEC include:

• Stephen Farr,
  President, Chief Executive Officer, Director
• Bradley Galer,
  Executive Vice President, Chief Medical Officer
• Michael Smith,
  Chief Financial Officer, Executive Vice President, Treasurer
• Gail Farfel,
  Executive Vice President, Chief Development Officer
• Ashish Sagrolikar,
  Executive Vice President, Chief Commercial Officer
• Dr. Stephen J. Farr,
  Co-Founder, CEO, Pres & Director
• Shawnte M. Mitchell,
  Exec. VP, Gen. Counsel & Sec.
• Dr. Bradley S. Galer,
  Exec. VP & Chief Medical Officer
• Dr. Gail M. Farfel,
  Exec. VP & Chief Devel. Officer
• Michael P. Smith,
  Exec. VP, CFO & Treasurer
• Ashish M. Sagrolikar,
  Exec. VP & COO
• Cam Garner,
  Independent Chairman of the Board
• Erle Mast,
  Independent Director
• Louis Bock,
  Independent Director
• Mark Wiggins,
  Independent Director
• James Breitmeyer,
  Independent Director
• Renee Tannenbaum,
  Independent Director
• Denelle Waynick,
  Independent Director
• Mary Stutts,
  Independent Director
• Caroline Loewy,
  Independent Director
• Shawnte Mitchell,
  Executive Vice President, General Counsel, Secretary
• Stephen H. Jenner,
  VP of Marketing
• Bret E. Megargel,
  VP of Corp. Devel.
• Melinda Baker,
  Sr. Director of Corp. Communications
• Jeff D. Durflinger,
  VP of Technical Operations & Product Supply
• Ann D Rhoads,
  EVP, CFO, Treasurer & Sec.
• Thierry J.P. Darcis,
  EVP / General Manager, Europe
• Venture Partners Ii, Lp Sca...,
  
• Growth Partners Ii L P Chic...,
  
• Advisors Llcperceptive Life...,
  
• Roger Hawley,
  Chief Executive Officer
• James C Blair,
  Director
• Richard Scott Shively,
  Chief Commercial Officer
• Nicole Vitullo,
  10% owner
• Ken Haas,
  Director
• Cynthia Y Robinson,
  Chief Development Officer
• Brian K Halak,
  10% owner
• Arda Phd Minocherhomjee,
  Director
• Kurt Wheeler,
  Director
• Kathleen K Schoemaker,
  10% owner
• Lifesciences I, L.P.Clarus ...,
  
• Parters Vii L P Domain,
  10% owner
• Vi Associates, L.P. Dp,
  10% owner
• Venture Partners Ii, Lp Sca...,
  
• Brian H Dovey,
  10% owner
• Partners Vi, L.P. Domain,
  10% owner
• Jesse I Treu,
  10% owner
• Mcnerney & Partners Lp Thom...,
  
• Vii Associates Lp Dp,
  10% owner
• Lifesciences I, L.P.Clarus ...,